FDA Meets With Clinical Decision Support Firms To Address Challenging Cases
This article was originally published in The Pink Sheet Daily
The agency recently sat down with members of the Clinical Decision Support Coalition who presented mock case studies of regulatory submissions for software supporting drug therapy decisions. The coalition hopes to get feedback on how FDA intends to regulate such software in the coming months.
You may also be interested in...
CDRH Guidance Priorities Include Lab-Developed Tests, Adverse Event Reporting, Third-Party 510(k) Review
FDA's device center issued its annual “A List” and “B List” guidance priorities for fiscal year 2016, spotlighting efforts to address Unique Device Identification direct marking, Medical Device Reporting rules, laboratory-developed tests, 510(k) third-party review, companion diagnostics, and more.
X-ray manufacturers and importers submitting Electronic Product Control reports will only need to submit their variance application package once.
The US FDA commissioner published a blog post commending and highlighting the work device center staff have done during the pandemic to speed tests and devices to market to save lives.